Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
Interventions: Standard Genetic Counseling, Educational Video; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Milford, Massachusetts + 3 more

Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma
Interventions: CART-TnMUC1, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 7 more

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions: gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions: SGN-STNV; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Telehealth Intervention, Usual Care; Behavioral · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Sitagliptin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Daytona Beach, Florida • Honolulu, Hawaii • Dallas, Texas

Conditions: Breast Cancer
Interventions: Adjuvant Radiotherapy; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Diabetes, Peripheral Neuropathy, Pain
Interventions: lidocaine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity & Overweight, Diabetes (DM)
Interventions: Glucagon-Like Peptide-1 Agonist (GLP-1); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus, Dehydration
Interventions: Hydration Plus, Control; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Osteoporosis
Interventions: Not listed
Lead sponsor: Oklahoma State University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Burns, Liver Fibroses, Pancreas Disease, Thyroid Diseases
Interventions: Ultrasound/transient elastography; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 6 Months and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
Interventions: Alomfilimab, Atezolizumab; Drug
Lead sponsor: Kymab Limited; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more

Conditions: Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: questionnaire administration, quality-of-life assessment; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tustin, California

Conditions: Diabetes Mellitus
Interventions: Insulin Detemir, Insulin Glargine; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Type 1 Diabetes
Interventions: Diabetes behavior change skills training, Physical activity promotion program; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 13 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis, Pancreatic Neuroendocrine Carcinoma, Pancreatic Adenocarcinoma
Interventions: medical chart review, survey administration, biospecimen collection; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
Interventions: Avastin, Docetaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more

Conditions: Diabetic Foot Ulcer
Interventions: PriMatrix Dermal Repair Scaffold, Secondary Dressings, Offloading device; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: Carlsbad, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Diabetic Neuropathy, Painful
Interventions: AGN 203818, placebo capsule; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions: Laboratory clotting studies; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 0 Hours to 2 Hours
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer

A Study of SGN-STNV in Advanced Solid Tumors

Telehealth Intervention for Youth With T1DM

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

Ultrasound Findings in Diabetic Pregnancies

Lidocaine for Diabetic Peripheral Neuropathy

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

Oklahoma Native American Women's Osteoporosis Screening Study

Liver, Pancreas and Thyroid Function in Burn Patients

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes

Technology-delivered Physical Activity Program for Adolescents With Type 1 Diabetes

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma

PriMatrix for the Management of Diabetic Foot Ulcers

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Thromboelastographic Profile in Healthy Newborns and Infants of Diabetic Mothers Using TEG6s